ePrints

Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin

Lookup NU author(s): Dr Keith Mitchell, James Talks

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Objective: To assess if posterior juxtascleral application of 40 mg triamcinolone acetonide (TA), given at the same time as initial photodynamic therapy (PDT) for predominantly classic choroidal neovascularization (CNV) related to age-related macular degeneration affects lesion growth at 3 and 6 months. Design: Comparative (nonrandomized) interventional study. Participants: The study group consists of 38 eyes of 38 patients. The control group consists of 73 eyes of 73 patients. Methods: Comparison of 2 consecutive case series collected at different times. The study group had a posterior juxtascleral TA with their initial PDT treatment. The controls were treated with PDT alone. All patients were reviewed at 1, 3, and 6 months. Main Outcome Measures: Change in total lesion size; secondary outcomes: area of leak, best-corrected visual acuity, number of treatments, and intraocular pressure. mm(2); Results: There was significantly less growth of total lesion at 3 months (mean difference = 2.47 mm(2) 95% confidence interval (CI): +1.22 to +3.72 mm(2); p = 0.0002) and 6 months (mean difference = 2.88 mm(2); 95% CI: +0.61 to +5.15 mm(2); p = 0.0134) in patients given TA with PDT compared with PDT alone. There was also a significantly smaller residual area of leak at 3 months in the study group (mean difference = 1.07 mm(2); 95% CI: +0.16 to +1.97 mm(2); p = 0.02). At 6 months, the residual area of leak between the 2 groups became comparable (mean difference = 0.13 mm(2); 95% CI = -1.59 to +11.33 mm(2); p = 0.86). Mean number of letters lost on the logarithm of the minimum angle of resolution chart at 6 months was 9.1 letters (standard error of the mean [SEM] = 2.21) in the study group compared with 12.4 letters (SEM = 1.91) in the control group (P = 0.30). At 6 months, 10 of 36 eyes (27.8%) in the study group showed >= 15 letters loss, compared with 29 of 73 eyes (39.7%) in the control group. Intraocular pressure was raised in 4 of 38 eyes (10.5%). Fewer retreatments were required in the TA with PDT group (2.03 compared with 2.47 [P = 0.006]). Conclusions: Posterior juxtascleral placement of TA with PDT at baseline significantly reduces CNV growth at 3 and 6 months. Fewer retreatments were required. Visual outcome may be improved, although we did not show a statistically significant improvement with this sample size. A larger, randomized trial with longer follow-up is justified.

Publication metadata

Author(s): Van de Moere A, Sandhu SS, Kak R, Mitchell KW, Talks SJ

Publication type: Article

Publication status: Published

Journal: Ophthalmology

Year: 2005

Volume: 112

Issue: 11

Pages: 1897-1903

ISSN (print): 0161-6420

ISSN (electronic): 1549-4713

Publisher: Elsevier Inc.

URL: http://dx.doi.org/10.1016/j.ophtha.2005.06.018

DOI: 10.1016/j.ophtha.2005.06.018

Altmetrics

Share